Repligen Co. (NASDAQ:RGEN) Given Consensus Rating of “Moderate Buy” by Analysts

Repligen Co. (NASDAQ:RGEN) has received an average rating of “Moderate Buy” from the fourteen research firms that are covering the stock, MarketBeat reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $178.64.

A number of brokerages recently commented on RGEN. Royal Bank of Canada boosted their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Finally, TD Cowen initiated coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock.

Repligen Price Performance

Shares of RGEN opened at $128.50 on Friday. The firm has a market cap of $7.22 billion, a PE ratio of -251.96, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. Repligen has a 52-week low of $113.50 and a 52-week high of $182.52. The business’s 50 day moving average price is $152.75 and its two-hundred day moving average price is $148.00. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, equities analysts anticipate that Repligen will post 1.72 EPS for the current year.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Signaturefd LLC increased its position in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after buying an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new stake in Repligen in the 4th quarter worth about $29,000. Raiffeisen Bank International AG purchased a new stake in Repligen in the 4th quarter worth about $29,000. Resources Management Corp CT ADV bought a new stake in Repligen in the 3rd quarter valued at about $37,000. Finally, Quarry LP lifted its holdings in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 239 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.